[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"necrosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:necrosis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100558632","necrosectomy-with-cryotechnology-for-accelerated-removal-100558632",false,"NCT06553651","Necrosectomy With Cryotechnology for Accelerated Removal","NECTAR","Inclusion Criteria:\n\n* Subjects aged 18 years and above, inclusive of both males and females.\n* Patients with symptomatic pancreatic necrosis resulting from acute pancreatitis, indicated for endoscopic necrosectomy following endoscopic ultrasound (EUS)-guided drainage.\n* Imaging indicative of ≥30% necrotic material within the pancreas.\n* Walled-off pancreatic necrosis (WOPN) size ≥6 cm.\n* Subjects able to tolerate repeated endoscopic procedures.\n* Capacity for providing informed consent.\n* Understanding of study requirements, provision of written informed consent, and willingness and ability to attend required follow-up assessments through 21 (+\u002F- 7) days.\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Unwillingness to undergo repeated endoscopies.\n* Presence of documented Pseudoaneurysm \\> 1cm within the WOPN.\n* Intervening gastric varices or unavoidable blood vessels within the access tract.\n* Use of dual antiplatelet therapy or therapeutic anticoagulation that cannot be temporarily discontinued.\n* Any condition deemed by the investigator to compromise the safety of undergoing an endoscopic procedure.\n* Pregnancy, lactation, or absence of reliable contraception in women of childbearing potential.\n* Current enrollment in another investigational trial with potential to interfere with this study's endpoint analyses.","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","Pancreatic necrosis is a serious complication of acute pancreatitis. Pancreatic necrosis involves the irreversible death of pancreatic tissue, which can lead to severe health issues, including infections and an increased risk of death. An endoscopic procedure called direct endoscopic necrosectomy (DEN) is typically performed to remove this necrotic pancreatic tissue as a minimally invasive treatment. This procedure is performed using a thin, flexible, lighted tube called an endoscope and endoscopic instruments that are used with working channels through the scope. Current methods for removing necrotic tissue involve using endoscopic devices such as snares, baskets, nets, and forceps. However, these standard methods are often not very effective because the necrotic tissue can be sticky and hard to grasp. This DEN procedure is part of regular clinical care to treat this condition and remove necrotic tissue from the pancreas.\n\nFor this research study, the same DEN procedure will be followed with the exception of the device used for the removal of the necrotic tissue. Instead of using forceps, snares, or other traditional tools, a cryoprobe will be used. Cryoprobes work by using extremely cold temperatures to freeze and adhere to the necrotic tissue, making it easier to remove. This method might be better because it can secure larger tissue samples and potentially reduce complications associated with traditional methods. Cryotechnology is successfully used in endoscopy to remove necrotic tissue, foreign bodies and more, but has not been extensively tested in pancreatic necrosis. Cryoprobes are FDA approved medical devices with an established safety record. They are used successfully in very sensitive areas such as the lungs. This study aims to evaluate the safety and effectiveness of cryotechnology for DEN.",[26,27,28,29,30,31],"Pancreatic Necrosis","Acute Pancreatitis","Acute Pancreatic Necrosis","Necrosis","Necrosis Pancreas","Walled-Off Pancreatic Necrosis",[33,34,35,36,37,38],"Direct Endoscopic Necrosectomy (DEN)","Endoscopic Necrosectomy","Pancreatic Necrosectomy","Necrosectomy","Cryotherapy","Cryotechnology","RECRUITING","2026-06-23",{"date":42,"type":43},"2026-06-25","ACTUAL",{"date":45,"type":20},"2026-12",{"date":47,"type":20},"2029-06",{"name":49,"class":50},"Christopher C. Thompson, MD, MSc","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":21,"phases":63,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":4},"100635453","pseudomembrane-removal-for-post-rt-nasopharyngeal-necrosis-100635453","NCT07552883","Pseudomembrane Removal for Post-RT Nasopharyngeal Necrosis","Endoscopic Nasopharyngeal Pseudomembrane Removal for Prevention of Radiation-Induced Nasopharyngeal Necrosis After Re-irradiation in Recurrent Nasopharyngeal Carcinoma: A Single-Arm, Multicenter Interventional Study","EPoRN","Inclusion Criteria:\n\n* Voluntarily sign the informed consent form.\n* Age between 18 and 80 years.\n* ECOG performance status ≤ 2.\n* Prior radical radiotherapy with total dose ≥ 66 Gy.\n* Imaging or histopathology confirmed local recurrence and\u002For retropharyngeal lymph node recurrence, with or without cervical lymph node recurrence.\n* Re-irradiation with single dose \\\u003C 2.3 Gy and total dose ≥ 50 Gy.\n* Presence of pseudomembrane reaction on nasopharyngeal mucosa during or after re-irradiation.\n* Expected survival \\> 1 year.\n* Induction chemotherapy, immunotherapy, concurrent chemotherapy, adjuvant chemotherapy, or radiotherapy alone are all permitted.\n\nExclusion Criteria:\n\n* History of other malignancies within the past 5 years, except cured non-melanoma skin cancer or carcinoma in situ of the cervix.\n* Severe uncontrolled systemic diseases (e.g., uncontrolled infection, severe cardiovascular disease, uncontrolled diabetes).\n* Pregnant or breastfeeding women.\n* Known allergy to any equipment or medication used during endoscopy.\n* Inability to tolerate endoscopic procedure due to anatomical or medical reasons.\n* Concurrent participation in another interventional clinical trial.\n* Any condition that, in the investigator's judgment, would interfere with study compliance or outcome assessment.","80 Years",{"count":62,"type":20},40,[23],"This study aims to evaluate the effectiveness and safety of endoscopic nasopharyngeal pseudomembrane removal in reducing radiation-induced nasopharyngeal necrosis in patients with recurrent nasopharyngeal carcinoma who have received re-irradiation. This is a prospective, single-arm, multicenter interventional study. Participants with recurrent nasopharyngeal carcinoma who develop pseudomembrane reaction during or after re-irradiation will receive endoscopic pseudomembrane removal. Based on published literature, the 2-year incidence of radiation-induced nasopharyngeal necrosis after re-irradiation is approximately 40%. This study expects to reduce the incidence to 20%. The primary outcome measure is the 2-year incidence of nasopharyngeal necrosis after re-irradiation. Secondary outcome measures include: necrosis-free survival, overall survival, progression-free survival, local regional recurrence-free survival, distant metastasis-free survival, as well as safety and adverse events. A total of 40 participants will be enrolled from multiple hospitals in China.",[66,67,29],"Nasopharyngeal Carcinoma (NPC)","Radiation Injuries",[69,70,71,72,73],"recurrent NPC","re-RT","radiation necrosis","pseudomembrane","endoscopy","NOT_YET_RECRUITING","2026-04-20",{"date":77,"type":43},"2026-04-27",{"date":79,"type":20},"2026-04-30",{"date":81,"type":20},"2031-04-30",{"name":83,"class":50},"Jiangxi Provincial Cancer Hospital"]